Pulmonary pathology in Gaucher's disease

doi:10.1016/S0046-8177(99)90092-8

Human Pathology

Volume 30, Issue 6, June 1999, Pages 666-670

https://doi.org/10.1016/S0046-8177(99)90092-8 Get rights and content

Abstract

Gaucher's disease is a familial storage disease caused by a deficiency of the enzyme glucocerebrosidase. Pulmonary involvement is considered rare in Gaucher's disease, especially type I. Sporadic case reports have shown various types of lung involvement, but the spectrum of pulmonary pathology in Gaucher's disease has not been described. Nine cases of Gaucher's disease were retrieved from the autopsy file of Hadassah Medical Center, Jerusalem, Israel. There were six cases with type I Gaucher's disease and three cases with type II. Lung sections were evaluated, and special stains were employed, including immunohistochemical stains for CD68, cytokeratin, and CD34. Gaucher cells were found in the lungs in all nine cases. The involvement was considered pathologically significant in five of nine cases and clinically significant in three of nine cases. Four distinct patterns of pulmonary involvement by Gaucher cells emerged: intracapillary (9 of 9), patchy interstitial infiltrates in a lymphatic distribution (2 of 9), massive interstitial thickening of alveolar septa (1 of 9), and intra-alveolar infiltrates (2 of 9). The universal involvement of pulmonary capillaries indicates that this is probably systemic in nature and not intrinsic to the lungs. Pulmonary involvement in Gaucher's disease is commoner than previously recognized. Immunocytochemical stains help to identify isolated Gaucher cells and distinguish them from native alveolar macrophages.

References (12)

RC Smith et al.
Unusual cardiac, renal and pulmonary involvement in Gaucher's disease: Interstitial glucocerebroside accumulation, pulmonary hypertension, and fatal bone marrow embolism
Am J Med
(1978)
J Benbassat et al.
Constrictive pericarditis in Gaucher's disease
Am J Med
(1968)
EL Schneider et al.
Severe pulmonary involvement in adult Gaucher's disease
Am J Med
(1977)
A Zimran et al.
Gaucher disease: Clinical, laboratory, radiologic and genetic features of 53 patients
Medicine
(1992)
E Beutler
Gaucher disease
N Engl J Med
(1991)
E Kerem et al.
Pulmonary function abnormalities in type I Gaucher disease
Eur Respir J
(1996)

There are more references available in the full text version of this article.

Cited by (74)

Pulmonary Manifestations of Endocrine and Metabolic Diseases in Children
2021, Pediatric Clinics of North America
Allogeneic hematopoietic stem cell transplantation for treating severe lung involvement in Gaucher disease
2020, Molecular Genetics and Metabolism Reports
Citation Excerpt :
Results of a 10-year follow-up in non-splenectomized patients were also significant: increase in hemoglobin levels and platelet count, decrease in liver and spleen volumes, improvement in DXA Z-scores, and reduction in bone crises [3]. Pulmonary involvement in Gaucher disease (GD) includes interstitial lung disease, alveolar/lobar consolidation, pulmonary hypertension, and hepatopulmonary syndrome [4]. It is less common than visceral, hematologic, and bone manifestations.
To provide strategies for monitoring and treating severe lung involvement in Gaucher disease.
We reviewed the chart of a 5-year-old boy who developed rapidly progressive, severe infiltrative lung involvement of Gaucher disease (GD) and improved after allogeneic hematopoietic stem cell transplant (HSCT), along with other case studies reported before December 2019. He was diagnosed with GD (homozygous mutation at c.1448 T > C, p.L483P), and started receiving enzyme replacement therapy (ERT) at 17 months old. He developed respiratory distress symptoms after 45 months of ERT; chest imaging reported diffuse interstitial infiltration of the bilateral lungs and consolidations at the right lungs. Allogeneic HSCT using cells from a matched unrelated donor was performed four months upon progressive respiratory symptoms.
His respiratory symptoms subsided in one month; chest imaging improvement, pulmonary function test improvement, and normalized activity of β-glucocerebrosidase were reported in three months.
This is the first report of a patient who received early and regular ERT but developed severe infiltrative lung involvement and recovered after allogeneic HSCT. Based on study results, we suggest regular chest imaging, even for asymptomatic patients. For patients with severe lung involvement, rapid deterioration, and unresponsive to higher ERT dosages, allogeneic HSCT should be considered.
Respiratory complications of metabolic disease in the paediatric population: A review of presentation, diagnosis and therapeutic options
2019, Paediatric Respiratory Reviews
Inborn errors of metabolism (IEMs) whilst individually rare, as a group constitute a field which is increasingly demands on pulmonologists. With the advent of new therapies such as enzyme replacement and gene therapy, early diagnosis and treatment of these conditions can impact on long term outcome, making their timely recognition and appropriate investigation increasingly important. Conversely, with improved treatment, survival of these patients is increasing, with the emergence of previously unknown respiratory phenotypes. It is thus important that pulmonologists are aware of and appropriately monitor and manage these complications. This review aims to highlight the respiratory manifestations which can occur. It is divided into conditions resulting primarily in obstructive airway and lung disease, restrictive lung disease such as interstitial lung disease or pulmonary alveolar proteinosis and pulmonary hypertension, whilst acknowledging that some diseases have the potential to cause all three. The review focuses on general phenotypes of IEMs, their known respiratory complications and the basic metabolic investigations which should be performed where an IEM is suspected.
Lessons from lung transplantation: Cause for redefining the pathophysiology of pulmonary hypertension in gaucher disease
2019, Respiratory Medicine Case Reports
Citation Excerpt :
PH in GD1 has been classified into WHO Group 5, for unclear or multifactorial mechanisms [11]. The classic pathophysiologic explanation for PH in GD1 is that Gaucher cells deposit in the pulmonary parenchyma and capillaries, thus obstructing blood flow [8,12]. However, severe PH in GD1 has been described with little-to-no evidence of Gaucher cells within the lungs [2,13].
Gaucher disease type 1 (GD1) is a lysosomal storage disease rarely resulting in end stage pulmonary hypertension (PH) and interstitial lung disease. There have only been two previous case reports of patients with GD1 receiving lung transplants.
We report a case of successful bilateral sequential lung transplantation in a patient with end-stage GD1-related PH. Prior to transplant, the patient was on enzyme replacement therapy with imiglucerase and pulmonary vasodilator therapy with bosentan, sildenafil and epoprostenol. The patient had pre-transplant comorbidities of prior splenectomy and osteopenia. She underwent bilateral sequential lung transplantation with basiliximab, methylprednisolone and mycophenolate mofetil induction. Her explanted lungs demonstrated severe pulmonary arterial hypertensive changes, but no Gaucher cells. She was maintained on MMF, tacrolimus, prednisone, imiglucerase and warfarin post-transplant. Her post-transplant course was complicated by hemorrhagic shock, prolonged support with extracorporeal membrane oxygenation, and acute renal failure requiring dialysis. Despite these complications, the patient was discharged and is doing well nine months post-transplantation.
This is one of only three reported cases of lung transplantation in patients with GD1. Each case has involved previously splenectomised, female patients with GD1. This is the first to report transplantation in a patient with severe PH and no pulmonary parenchymal disease. As evidenced in our patient, long term treatment with imiglucerase may eliminate the Gaucher cells in the lungs. The PH in these patients is most consistent with pulmonary arterial hypertension, raising the question of whether this should be reclassified as WHO Group 1 PH.
Histological characterisation of visceral changes in a patient with type 2 Gaucher disease treated with enzyme replacement therapy
2018, Blood Cells, Molecules, and Diseases
Gaucher disease is a lysosomal storage disease caused by deficiency of glucocerebrosidase and accumulation of glucocerebroside. Three major sub-types have been described, type 2 is an acute neurological form that exhibits serious general symptoms and poor prognosis, compared with the other types. This case was a girl diagnosed with type 2 Gaucher disease at 12 months of age who presented with poor weight gain from infancy, stridor, hypertonia, hepatosplenomegaly, trismus and an eye movement disorder. Enzyme replacement therapy (ERT) was administered, but she had frequent myoclonus and developmental regression. She needed artificial ventilation because of respiratory failure. She died at 11 years of age. An autopsy demonstrated infiltrating CD68-positive large cells containing abundant lipids in alveoli, while in the liver, kidney and bone marrow CD68-positive cells were small and round. In the bone marrow, myelodysplastic changes were present without Gaucher cells. The infiltration of Gaucher cells in alveoli was marked, suggesting that ERT was relatively ineffective in pulmonary involvement, particularly intra-alveolar. Additional treatments are necessary to improve the neurological and pulmonary prognosis of type 2Gaucher disease.
Gaucher disease: A diagnostic challenge for internists
2014, European Journal of Internal Medicine
Gaucher disease (GD), the most common inherited lysosomal storage disorder, is a multiorgan disease due to an autosomal recessive defect of the gene encoding glucocerebrosidase enzyme, responsible for the accumulation of glucosylceramide (glucocerebroside) into reticuloendothelial cells, particularly in the liver, spleen and bone marrow. GD is a clinically heterogeneous disorder and it is conventionally classified in type 1 (non-neuronopathic disease), types 2 and 3 (acute and chronic neuronopathic disease, respectively). Features of clinical presentation and organ involvement as well as age, at presentation are highly variable among affected patients. Splenomegaly and/or thrombocytopenia are the most common presenting features either as incidental findings during routine blood count or physical examination. Other possible clinical manifestations can be hepatomegaly with abnormal liver function tests, bone pain often associated with skeletal complications (pathological fractures, avascular necrosis, osteopenia), pulmonary hypertension and, in neuronopathic forms, neurological manifestations (dysfunction of eye motility, mild mental retardation, behavioural difficulties, choreoathetosis and cramp attacks). For all these reasons GD diagnosis is often a real challenge for internists. In the presence of clinical suspicion of GD, the diagnosis has to be confirmed measuring the betaglucocerebrosidase activity in the peripheral leukocytes and by molecular analysis. Each patient needs an accurate initial multisystemic assessment, staging the damage of all the possible organs involved, and the burden of the disease, followed by regular followup. The correct and early diagnosis permits to treat patients properly, avoiding the complications of the disease.

View all citing articles on Scopus

View full text

Original contributionPulmonary pathology in Gaucher's disease

Abstract

Am J Med

Am J Med

Am J Med

Gaucher disease: Clinical, laboratory, radiologic and genetic features of 53 patients

Medicine

Gaucher disease

N Engl J Med

Pulmonary function abnormalities in type I Gaucher disease

Eur Respir J

Original contribution
Pulmonary pathology in Gaucher's disease